Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. (Registro nro. 15907)
[ vista simple ]
000 -CABECERA | |
---|---|
Campo de control de longitud fija | nab a22 7a 4500 |
003 - IDENTIFICADOR DEL NÚMERO DE CONTROL | |
Campo de control | PC15907 |
005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN | |
Campo de control | 20201217104220.0 |
008 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA | |
Campo de control de longitud fija | 200504b xxu||||| |||| 00| 0 eng d |
040 ## - FUENTE DE LA CATALOGACIÓN | |
Centro transcriptor | H12O |
041 ## - CÓDIGO DE LENGUA | |
Código de lengua del texto/banda sonora o título independiente | eng |
100 ## - PUNTO DE ACCESO PRINCIPAL - NOMBRE DE PERSONA | |
9 (RLIN) | 2655 |
Nombre de persona | García González, A. Javier |
Término indicativo de función | Reumatología |
245 00 - MENCIÓN DE TÍTULO | |
Título | Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. |
Tipo de material | [artículo] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Nombre del editor distribuidor etc. | Rheumatology (Oxford), |
Fecha de publicación distribución etc. | 2014 |
300 ## - DESCRIPCIÓN FÍSICA | |
Extensión | 53(12):2223-31. |
500 ## - NOTA GENERAL | |
Nota general | Formato Vancouver: Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014 Dec;53(12):2223-31. |
501 ## - NOTA DE “CON” | |
Nota de "Con" | PMID: 24996907 |
504 ## - NOTA DE BIBLIOGRAFÍA; ETC. | |
Nota de bibliografía etc. | Contiene 53 referencias |
520 ## - NOTA DE SUMARIO; ETC. | |
Sumario etc. | Objective: The aim of this study was to assess the efficacy of anti-TNF-α therapy in refractory uveitis due to Behçet's disease (BD). Methods: We performed a multicentre study of 124 patients with BD uveitis refractory to conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. Patients were treated for at least 12 months with infliximab (IFX) (3-5 mg/kg at 0, 2 and 6 weeks and then every 4-8 weeks) or adalimumab (ADA) (usually 40 mg every 2 weeks). The main outcome measures were degree of anterior and posterior chamber inflammation, visual acuity, macular thickness and immunosuppression load. Results: Sixty-eight men and 56 women (221 affected eyes) were studied. The mean age was 38.6 years (s.d. 10.4). HLA-B51 was positive in 66.1% of patients and uveitis was bilateral in 78.2%. IFX was the first biologic agent in 77 cases (62%) and ADA was first in 47 (38%). In most cases anti-TNF-α drugs were used in combination with conventional immunosuppressive drugs. At the onset of anti-TNF-α therapy, anterior chamber and vitreous inflammation was observed in 57% and 64.4% of patients, respectively. In both conditions the damage decreased significantly after 1 year. At baseline, 50 patients (80 eyes) had macular thickening [optical coherence tomography (OCT) >250 μm] and 35 (49 eyes) had cystoid macular oedema (OCT>300 μm) that improved from 420 μm (s.d. 119.5) at baseline to 271 μm (s.d. 45.6) at month 12 (P < 0.01). The best-corrected visual acuity and the suppression load also showed significant improvement. After 1 year of follow-up, 67.7% of patients were inactive. Biologic therapy was well tolerated in most cases. Conclusion: Anti-TNF-α therapy is effective and relatively safe in refractory BD uveitis. |
710 ## - PUNTO DE ACCESO ADICIONAL - NOMBRE DE ENTIDAD | |
9 (RLIN) | 123 |
Nombre de entidad o nombre de jurisdicción como elemento inicial | Servicio de Reumatología |
856 ## - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS | |
Identificador Uniforme del Recurso (URI) | http://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc15907.pdf |
Acceso | Solicitar documento |
942 ## - ENTRADA PARA ELEMENTOS AGREGADOS (KOHA) | |
Fuente de clasificación o esquema de ordenación en estanterías | |
Koha [por defecto] tipo de item | Artículo |
Suprimido en OPAC | Público |
Suprimido | Estado de pérdida | Fuente de clasificación o esquema de ordenación en estanterías | Estropeado | No para préstamo | Localización permanente | Localización actual | Fecha de adquisición | Signatura completa | Fecha última consulta | Fecha del precio de reemplazo | Tipo de item de Koha |
---|---|---|---|---|---|---|---|---|---|---|---|
Hospital Universitario 12 de Octubre | Hospital Universitario 12 de Octubre | 2020-05-04 | PC15907 | 2020-05-04 | 2020-05-04 | Artículo |